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Abstract Patients with diabetes are at high risk for
polypharmacy (ie, use of multiple medications) for
treatment of diabetes, associated comorbidities and other
coexisting conditions. This study aims to estimate the
prevalence of polypharmacy and factors associated with
polypharmacy among adult patients with diabetes.
Methods A cross-sectional retrospective observational
study of adults with diabetes, who visited the outpatient
clinic of a tertiary teaching hospital in Saudi Arabia, was
conducted. Data were extracted from the Electronic Health
Record database for a period of 12 months (January–
December 2016). Polypharmacy was defined as the
cumulative use of five or more medications. Polypharmacy
among adults with diabetes was measured by calculating
the average number of medications prescribed per patient.
A multivariable logistic regression model was used to
examine the factors associated with polypharmacy.
Results A total of 8932 adults with diabetes were
included in this study. Of these, nearly 78% had
polypharmacy which was more likely among women
as compared with men and more likely among older
adults (age ≥60 years) as compared with the adults. Also,
polypharmacy was two times as likely among patients
with coexisting cardiovascular conditions (adjusted OR
(AOR)=2.89; 95% CI 2.54 to 3.29), respiratory disease
(AOR=2.42; 95% CI 1.92 to 3.03) and mental health
conditions (AOR=2.19; 95% CI 1.74 to 2.76), and
three times as likely among patients with coexisting
musculoskeletal disease (AOR=3.16; 95% CI 2.31 to 4.30)
as compared with those without these coexisting chronic
conditions categories.
Conclusions Polypharmacy is common among patients
with diabetes, with an even higher rate in older adults
patients. Healthcare providers can help in detecting
polypharmacy and in providing recommendations
for simplifying medication regimens and minimising
medications to enhance the outcome of diabetes care.

Introduction
Diabetes is a highly prevalent chronic condition among adults in Saudi Arabia; between
21% and 24% of adults are estimated to have
diabetes.1 2 It is projected that 27% of adults
in Saudi Arabia will have diabetes by 2035.3
Diabetes is 1 of the top 10 causes of morbidity

Strengths and limitations of this study
►► This study has provided a real insight into the current

prevalence and predictors of polypharmacy among
patients with diabetes in Saudi Arabia including a
large study population of patients with diabetes.
►► Around 9000 patients were included in this study
which allowed us to identify the prevalence of polypharmacy among a subgroup of patients.
►► This study has not controlled for the severity of diabetes using the Diabetes Complications Severity
Index which may affect the rate of polypharmacy.
►► This study used a 12-month period to measure multiple medications use which is not concurrent use
and may have resulted in a very high rate of multiple
medications uses.
►► It has to be noticed that not all polypharmacy is
harmful; however, future studies to assess inappropriate medications associated with polypharmacy is
warranted.

and mortality worldwide.4 Patients with
diabetes often have coexisting chronic health
conditions such as hypertension, dyslipidaemia, coronary artery disease, depression
and chronic kidney disease, which requires
the use of multiple medications to treat those
coexisting chronic conditions.5 All of this put
patients with diabetes at high risk of polypharmacy,6 7 with an estimated prevalence
of 57%–84% of patients with diabetes using
five or more medications.8 A study among
adults with diabetes in the USA documented
that the 54% of adults with diabetes have
polypharmacy.9 A multicentre cross-sectional
survey conducted in Italy reported that 57%
of patients with diabetes use five or more
medications.10 In addition, polypharmacy was
reported among 84% older adults patients
with diabetes.8 In Saudi Arabia, a cross-sectional study among 766 adults who visited
outpatient’s clinic at a tertiary care centre,
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reported that the prevalence of polypharmacy among
patients with diabetes was 71%.11
An examination of polypharmacy among patients with
diabetes is important because polypharmacy increases
the probability of the adverse drug events,12 13 drug–drug
interactions,14 duplication of therapy,15 decreases compliance to antidiabetic medications16 and leads to suboptimal
glycaemic control.17 The presence of polypharmacy is
also associated with prescribing cascade, in which adverse
drug events are misinterpreted as new medical conditions which can result in the prescription of new medications to treat those conditions.18 Polypharmacy has other
negative health consequences such as increased risk of
hospitalisation and medication error,19 20 higher risk of
fall,21 poor functional status,22 poor quality of life and
high healthcare cost.23 24 Polypharmacy among patients
with diabetes is often associated with many factors. These
include age,11 sex,10 coexisting conditions,10 rurality,11 25
diabetes complications10 and aggressive diabetes treatment.26 27
To date, limited studies have examined the prevalence of
polypharmacy among adults with diabetes living in Saudi
Arabia on a large scale, and assessed the specific factors
that put patients at risk of polypharmacy. Identifying the
prevalence and the subgroup of patients at high risk of
polypharmacy will facilitate pharmacovigilance efforts in
clinical practice settings. Therefore, the primary objective
of this observational study is to examine the prevalence
of polypharmacy among adults with diabetes in Saudi
Arabia and to identify the factors that are associated with
polypharmacy, specifically the association between coexisting chronic conditions and polypharmacy.

Methods
Study design
A cross-sectional retrospective observational study was
conducted in a tertiary teaching hospital in Saudi Arabia.
This hospital is one of the largest tertiary teaching hospitals in Riyadh, Saudi Arabia, with a 1200-bed facility and
all general and subspecialty medical services. The hospital
provides primary, secondary and tertiary care services.
The patient population is composed predominantly of
local citizens as well as residents, from Northern region
in Riyadh; the hospital also serves the entire country as a
referral centre.
Data source and data extraction
This study used data retrieved from the Electronic Health
Record (EHR) database for the period from 1 January
2016 to 30 December 2016. Strict confidentiality of the
data was maintained throughout the research process.
The data from EHR were derived from demographics
file, clinical diagnosis file and prescription drug file.
The demographics file contained information about the
patients’ date of birth, gender, marital status, nationality and encounter type. The clinical diagnosis file
provided information about the clinical diagnosis from
2

inpatient and outpatient visits. Physicians reported clinical diagnosis using the International Classifications of
Diseases, ninth edition, Clinical Modification (ICD-9-CM)
codes, ICD-10th edition, CM codes or the Systematised
Nomenclature of Medicine diagnosis codes. The prescription drug file contained information about the medications used. The demographics, clinical diagnosis and
prescription drug files were merged into one file using the
encrypted patient medical record number. The completeness and the validity of the data from EHR in this tertiary
teaching hospital in Saudi Arabia has not been studied
before; however, the researchers of this study examined
the completeness of this data and found that 91.0% of
the patients had a complete data (ie, have information
on the age, gender, marital status, nationality, encounter
type and clinical diagnosis) and 85.0% of the patients had
complete medication-related information.
Study population
The study population comprised all adult patients with
diabetes (type 1 and type 2) (age ≥18 year) (n=8932) who
received their treatment at the outpatient’s setting in
the tertiary teaching hospital during a 1-year period. No
exclusion criteria were applied to the study population.
Patient and public involvement
Patients and public were not involved in the design or
conduct of this study.
Measures
Dependent variable
In our study, the dependent variable was ‘polypharmacy’. There are different approaches in the literature to
measure polypharmacy such as simultaneous, cumulative
and continuous. Also, there is no consensus on the thresholds regarding the number of medications above which we
consider the existence of polypharmacy.28 In the current
study, we defined polypharmacy as the cumulative use
of five or more medications during a 1-year period, this
threshold has been used more than others.25 28 29 Using
this definition, the prevalence of polypharmacy among
adults was measured by the sum of unique therapeutic
medication classes administered over a 12-month period.
There is no consensus on the medications that should be
included in the measurements of the polypharmacy. Also,
all the prescription and the non-prescription/over-thecounter (OTC) medications categories were included in
our definition of polypharmacy.
Independent variables
Independent variables included were age groups in years
(18–29, 30–39, 40–49, 50–59, 60–69, 70–79, >80), gender,
nationality (Saudi, non-Saudi), marital status (married,
unmarried) and documented chronic conditions which
were classified into five categories (cardiovascular, chronic
kidney disease, musculoskeletal, respiratory or mental
health conditions) (online supplementary appendix 1).
Cardiovascular conditions composed of hypertension,
ischaemic heart disease, vascular heart disease, stroke,
Alwhaibi M, et al. BMJ Open 2018;8:e020852. doi:10.1136/bmjopen-2017-020852
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heart failure and dyslipidaemia. Musculoskeletal conditions composed of osteoarthritis and osteoporosis; respiratory conditions include asthma and chronic obstructive
pulmonary disease (COPD). Mental health conditions
include dementia, depression, anxiety and schizophrenia.
These conditions have been selected because they are
highly prevalent among patients with diabetes and some
of them were associated with polypharmacy.5 30
Statistical analysis
Frequency and percentage were used to describe the categorical variables (age, sex, marital status, nationality, coexisting chronic conditions and polypharmacy). Mean and
SD were used to describe continuous variables. χ2 tests were
used to examine the factors associated with polypharmacy.
A multivariable logistic regression was used to examine the
factors associated with polypharmacy (ie, use of ≥5 medications) after adjusting for age, sex, marital status, nationality
and coexisting chronic conditions. All statistical analyses
were carried out using the SAS V.9.2.

(95.2%, p<0.001), musculoskeletal (93.6%, p<0.001),
respiratory (89.0%, p<0.001) and mental health conditions (85.4%, p<0.001) as compared with those without
those coexisting chronic conditions.
Logistic regression: factors associated with polypharmacy
The adjusted ORs (AORs) and 95% CIs from multivariable logistic regression on polypharmacy are displayed in
table 3. Several factors were identified: age, gender and
coexisting chronic conditions. Polypharmacy was more
likely among older adults as compared with younger
adults. Women were more likely to have polypharmacy
compared with men (AOR=1.60; 95% CI 1.43 to 1.79).
Cardiovascular diseases, mental conditions, respiratory
and musculoskeletal diseases were all significantly associated with polypharmacy. For example, adults with diabetes
and musculoskeletal disease were three times more likely
to have polypharmacy (AOR=3.16; 95% CI 2.31 to 4.30) as
compared with adults with diabetes and without musculoskeletal conditions.

Polypharmacy among patients with diabetes
Overall, 77.9% of adults with diabetes have used (cumulative) five or more medications. Also, when we identified
the rate of hyperpolypharmacy (ie, taking 10 or more
medications), we found that 17.2% of adults have a hyperpolypharmacy. The most commonly used medications
in our study population were antidiabetic medications
(81.4%), followed by non-steroidal anti-inflammatory
drugs (NSAIDs) (72.4%) and antihyperlipidaemic agents
(68.8%) (table 2).
The study population characteristics by polypharmacy
status are summarised in table 1. This study found a
significantly higher percentage of polypharmacy among
older adults as compared with patients with age between
18 and 29 years (84.8% vs 37.4%, p<0.001). Women
with diabetes had a significantly higher percentage of
polypharmacy as compared with men (81.7% vs 71.6%,
p<0.001). Moreover, polypharmacy was significantly
higher among patients with diabetes with two or more
coexisting comorbid conditions versus those with no
coexisting chronic conditions (89.6% vs 48.6%, p<0.001).
Looking at comorbid conditions closely, polypharmacy
was significantly higher among patients with cardiovascular disease (83.4%, p<0.001), chronic kidney disease

Discussion
Our study was set out to examine the prevalence of polypharmacy among adults with diabetes in Saudi Arabia. In
this large sample of subjects with diabetes, the rate of polypharmacy was high, as nearly four out of five adults with
diabetes were prescribed five or more medications. Similar
rates were reported in the literature among patients with
diabetes 54%–84%,8–10 however, to our knowledge, no
study has attempted to measure the rate of polypharmacy
among all age groups of adults with diabetes, which is a
major contribution of our study. A higher rate of polypharmacy among older individuals (age 60 and above)
as compared with all age groups was also observed in this
study. Studies among adults in the general population
have reported that older adults (defined as age >60 or
age >65 years) have a higher risk of polypharmacy use as
compared with adults.31 32 One possible reason for the
high rate of polypharmacy among this population is the
coexistence of other chronic conditions.
Furthermore, a noteworthy finding of the current
study is the high prevalence of chronic conditions and
the higher rate of polypharmacy among diabetic individuals with coexisting chronic conditions. Previous studies
have shown that 90% of patients with diabetes had at least
one coexisting chronic condition,5 our study found that
86% of patients with diabetes had at least one coexisting
chronic condition. It is plausible that the high rate of
polypharmacy in this study is potentially associated with
the number of comorbidities among the study population. The findings of this study support that patients with
diabetes with multiple chronic conditions were at higher
risk of polypharmacy.5 33 Although there is a well-documented literature on the relationship between the
higher number of coexisting conditions and polypharmacy,5 10 34 our study extended the literature by analysing
the association between the type of chronic conditions
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Results
A total of 8932 adult patients were identified during the
12-month period. The majority were Saudi (89.4%),
female (62.2%) and 43.3% of the study population were
older adults (age ≥60 years), the mean age of the study
population was 57 years old. About half of the subjects
(54.1%) had two or more diagnosed coexisting chronic
health conditions. Hypertension, dyslipidaemia, asthma,
osteoarthritis and anxiety were among the most common
chronic conditions in our study population. Characteristics of the study population are presented in table 1.

4

57.7 (12.12)

Age mean (SD)

1226

3176

2434

1126

 40–49

 50–59

 60–69

 70–79

 No
Respiratory conditions

 Yes

Musculoskeletal conditions

8145

787

7209

1723

 Yes

 No

Cardiovascular conditions

146

8786

 No

946

91.2

8.8

19.3

80.7

98.4

1.6

10.6

89.4

62.2

5557

7957

37.8

 Yes

Chronic kidney disease

 Non-Saudi

 Saudi

Nationality

 Female

 Male

88.4

11.6

3.5

12.6

27.3

35.6

13.7

5.2

2.2

100.0

3375

7310

 Married

Gender

957

 Single

Marital status

309

463–

 30–39

 ≥80

198

 18–29

Age group

8932
6.54 (3.50)

Total
# of medications mean(SD)

6220

737

942

6015

6818

139

768

6167

4539

2418

5769

635

269

951

1909

2521

830

253

74

59.7 (11.3)

6957
8.06 (2.97)

Polypharmacy
N

%

Total

N

76.4

93.6

54.7

83.4

77.6

95.2

81.2

77.5

81.7

71.6

78.9

66.4

87.1

84.5

78.4

79.4

67.7

54.6

37.4

77.9

%

1925

50

781

1194

1968

7

178

1790

1018

957

1541

322

40

175

525

655

396

210

124

52.7 (12.68)

1975
2.85 (1.14)

N

23.6

6.4

45.3

16.6

22.4

4.8

18.8

22.5

18.3

28.4

21.1

33.6

12.9

15.5

21.6

20.6

32.3

45.4

62.6

22.1

%

No polypharmacy

76.8

124.4

668.1

25.8

6.6

122.8

76.5

517.7

X2value

***

***

***

***

**

***

***

***

Continued

Significance

Table 1 Characteristics of the study population number and row percentage of characteristics by polypharmacy among adults with diabetes, Electronic Health Records
database, 2016
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29.2
10.4

51.4
643

831
501
70.8
89.6

48.6
607

2018
4332
31.9
54.1
2849
4833
 Single coexisting condition
>2 coexisting conditions

14.0
1250
 No coexisting conditions

# Chronic conditions

14.6

Study population comprised 8932 adults with diabetes (age >18 years) who visited outpatient’s clinics from a tertiary hospital in 2016. Polypharmacy was defined as the
cumulative use of five or more medications during the 1-year period.
#, Number.
Asterisks (*) represent significant differences in polypharmacy from X2 tests.
*P<0.001, **0.001<P<0.01.

***
1093.8
1863

112
85.4

77.2
6303

654
8.6

 No

91.4

766

8166

 Yes

 No

 Yes

22.8

27.3
23.4
1869
76.6
89.2
7971

6102

89.0
10.8
961

%

855
N
N

Continued
Table 1

Mental health conditions

11.0
106

%
N

Polypharmacy
Total

%

No polypharmacy

X2value

***

Significance
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Table 2 Most prevalent therapeutic classes among the
study population (n=8932)
Medication therapy class

N

%

 Oral antidiabetic agent
7270
 Non-steroidal anti-inflammatory drugs 6467

81.4
72.4

 Antihyperlipidaemic agents

6144

68.8

 Proton pump inhibitor

2540

28.4

 ACE inhibitor

2321

25.9

 Injectable antidiabetic agent

2253

25.2

 Calcium channel blocker

2162

24.2

 Corticosteroid, local

1892

21.1

 Diuretic

1934

21.6

 Beta-adrenergic blocker, beta-1
selective

1806

20.2

 Angiotensin II receptor blocker

1796

20.1

 Thyroid analogue

1355

15.1

 Histamine H2 blocker

822

9.2

 Anticoagulants

706

7.9

 Corticosteroid, systemic
 Antiplatelet

600
357

6.7
4.0

and polypharmacy. We observed that the polypharmacy
rates differed by the type of coexisting chronic conditions; with the highest use among those with musculoskeletal conditions. This is not surprising because individuals
with musculoskeletal conditions such as osteoarthritis use
analgesic and NSAIDs to relieve the chronic pain. We also
observed that patients with cluster of diseases (diabetes
and cardiovascular diseases) have a higher rate of polypharmacy as compared with adults without the cluster
of diseases which is consistent with the published literature.31 35 Patients with diabetes and mental health conditions have also a high rate of polypharmacy as compared
with those without mental health conditions. Further
studies are required to explore the contributing factors,
as there is no supporting evidence in the literature. Polypharmacy was also highly prevalent among patients with
diabetes and respiratory diseases, which is consistent with
data from previous studies, which showed higher rates of
medication use in patients with COPD.36
Accordingly, healthcare providers need to routinely
monitor these individuals for potentially inappropriate
medications, adverse drug events and drug–drug interactions. For instance, in older individuals, comprehensive geriatric assessment has shown effective impact in
decreasing the number of medications prescribed.37
Further, patients with diabetes and polypharmacy may
benefit from multidisciplinary collaborative care model
that involves pharmacist follow-up for the patients
to assess the medication use and minimise polypharmacy. In an open-label, parallel-arm, randomised,
controlled study, collaborative care has been associated
with improvement in the management of diabetes and
5
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Table 3 AORs and 95% CIs logistic regression on
polypharmacy adults with diabetes, Electronic Health
Records Database, 2016
AOR

95% CI

Significance

 30–39 vs 18–29

1.48

(1.00 to 2.18)

**

 40–49 vs 18–29

2.13

(1.47 to 3.08)

***

 50–59 vs 18–29

3.54

(2.46 to 5.11)

***

 60–69 vs 18–29

5.11

(3.51 to 7.44)

***

 70–79 vs 18–29

7.59

(5.07 to 11.35)

***

 
>80 vs 18–29

9.65

(5.69 to 16.38)

***

1.16

(0.96 to 1.40)

1.60

(1.43 to 1.79)

***

1.81

(1.50 to 2.19)

***

2.89

(2.54 to 3.29)

***

3.16

(2.31 to 4.30)

***

2.42

(1.92 to 3.03)

***

2.19

(1.74 to 2.76)

***

Age group

Marital status
 Single versus married
Gender
 Female versus male
Nationality
 Non-Saudi versus Saudi
Cardiovascular conditions
 Yes versus no
Musculoskeletal conditions
 Yes versus no
Respiratory conditions
 Yes versus no
Mental health conditions
 Yes versus no

Based on 8932 adults with diabetes, who visited outpatient’s
clinics from a tertiary hospital in 2016. Polypharmacy was defined
as the cumulative use of five or more medications during the
1-year period.
Asterisks (*) represent significant differences on polypharmacy
compared with the reference group based on logistic regression.
*P<0.001, **0.001<P<0.01.
AOR, adjusted OR.

reduction the healthcare cost.38 Pharmacists can help
other healthcare providers in detecting polypharmacy,
drug interactions and in providing recommendations
for simplified medication regimens and minimising
medications to positively impact health outcomes of
diabetes care.39 40
We also looked at other related factors for polypharmacy. We observed that women were more likely
to have a polypharmacy compared with men, this is
consistent with the findings from data among patients
with diabetes.10 In addition, studies have reported that
women in the general population have a higher use of
prescribed and non-prescribed medications, and higher
healthcare utilisation as compared with men.41–44 This
could be because women tend to be more concerned
about their health and seek health services more often
than men.45 It has to be noted that the majority of
patients with diabetes in our study were women, this
is not surprising since the rate of diabetes is higher in
women as compared with men in Saudi Arabia.2
6

Strengths and limitations
This study has some limitations; we defined polypharmacy as the cumulative use of five or more medications
during a 1-year period rather than the concurrent
use of medications, using this definition may have
overestimated the rate of polypharmacy. We did not
control for the severity of diabetes using the Diabetes
Complications Severity Index, which may affect the
rate of polypharmacy. We have also only observed filled
prescriptions and not actual use of the medications. By
using the EHR data, we cannot eliminate some risk of
bias; inaccurate information or missing data related to
the use of EHR. Due to the cross-sectional nature of
the data, it is difficult to assess any causal relationships.
People with the end-of-life care were included in the
study, which may have also overestimated the rate of
polypharmacy.46 Moreover, we have included all therapeutic medication classes, including OTC medications
and vitamins in our definition, which may have overestimated the rate of polypharmacy. It has to be noticed
that not all polypharmacy is harmful; however, we have
not assessed if the polypharmacy was appropriate or
not. This study was conducted in a tertiary hospital in
Riyadh; therefore, the findings from this study cannot
be generalised to primary care settings or to other
regions in Saudi Arabia. In addition, we cannot exclude
selection bias; patients included in this study may be
sicker, have sever diabetes and higher rates of comorbidities as compared with individuals seen in primary
care settings.
Despite these limitations, this study has many advantages such as the use of large sample size, which allowed
us to identify the prevalence of polypharmacy among a
subgroup of patients. Furthermore, findings from this
study added to the existing literature on the prevalence
of polypharmacy among all age groups and identified
the individuals who have a high risk of polypharmacy
based on their comorbidities. In addition, our results
highlighted the need for routine monitoring of highrisk individuals for drug-related problems. Therefore,
future studies are required to identify the rate of polypharmacy among other healthcare settings and assess
the impact of pharmacist-led interventions on the rate
of polypharmacy in patients with diabetes.
Conclusion
Polypharmacy is very common among adults with
diabetes; particularly among individuals with multiple
chronic conditions. Older adults patients have a
higher rate of polypharmacy, which could be due to
the increased number of multiple chronic conditions
in this population. Moreover, patients with coexisting
cardiovascular, mental and musculoskeletal chronic
conditions are at a high risk of polypharmacy. Individuals with diabetes may benefit from simplified
treatment regimens; thereby enhancing the health
outcomes of this population.
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Ethics and data confidentiality
Confidentiality of the data was maintained throughout
the research process. Retrieved data were stored and
saved as coded excel files. A customised formula was
used to generate the study-encrypted identification
assigned to each participant and replaced patients’
medical record number. Data extracted were stored at
the research unit at the tertiary hospital on secured,
password-protected and limited accessed computers.
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